Article Title: Novel Repositioning Therapy for Drug-Resistant Glioblastoma: In Vivo Validation Study of Clindamycin Treatment Targeting the mTOR Pathway and Combination Therapy with Temozolomide
Figure Lengend Snippet: Effect of clindamycin on the phosphorylation of p70S6K and S6 in glioblastoma cell lines. Dose responses of clindamycin (CLD) on the phosphorylation of p70S6K at Thr389 and S6 at Ser240/Ser244 in glioblastoma cell lines. Cells were treated with CLD (0, 110, 220, or 440 μM) for 72 h and subjected to Western blotting. The levels of phosphorylated and total p70S6K were indicated at the corresponding bands ( A , C , E , G ). Western blotting analysis was subjected to densitometric quantification after standardizing the ratio of phospho/total p70S6K (below panel). The phosphorylation and total S6 levels in glioblastoma cell lines were similarly analyzed via Western blotting ( B , D , F , H ). β-actin was used as the internal control level in all cases. Data are shown as the mean ± SE, similar results shown were representative of three independent experiments. Each group was compared to the 0 concentration level to determine statistical significance. (* p
Article Snippet: Western blotting was performed using anti-phospho-p70S6K (Thr389) (1:500), anti-phospho-S6 (Ser240/244) (1:1000), anti-S6 (1:4000), anti-phospho-4EBP1 (Thr37/46) (1:1000), and anti-β-actin (1:4000) polyclonal antibodies (Cell Signaling Technologies, Danvers, MA, USA).
Techniques: Western Blot, Concentration Assay